Back to your search result

Description

A cell-permeable quinolinyl-benzothiazolamine compound that is reported to act as a RIP3-selective kinase inhibitor with &,amp,amp,amp,gt,1,000-fold selectivity over a vast majority of more than 300 other kinases, including RIP1. RIP1 inhibitor Nec-1 (30 &,amp,amp,amp,micro,M, Cat. Nos. 480065 &,amp,amp,amp, 505224) and genetic knockdown can be employed in conjunction with GSK&,amp,amp,prime,872 (3 &,amp,amp,micro,M) in delineating RIP1- vs. RIP3-dependency in Toll-like receptors- (TLRs) mediated necrosis and TNFR1-initiated necroptosis in the presence or absence of caspase inhibitor Z-VAD-FMK (25 &,amp,amp,amp,micro,M, Cat. Nos. 627609 &,amp,amp,amp, 627610). While RIP3 and its downstream substrate MLKL are shown to mediate TLR3-initiated necrosis in the presence of Z-VAD-FMK in murine macrophage (BMDM &,amp,amp,amp, J774), fibroblast (3T3-SA &,amp,amp,amp, MEF), and endothelial (SVEC4-10) cultures, only in BMDM &,amp,amp,amp, J774 macrophage cultures is RIP1 involvement also seen in TLR3-mediated necrosis., A cell-permeable quinolinyl-benzothiazolamine compound that is reported to act as a RIP3-selective kinase inhibitor with &,gt,1,000-fold selectivity over a vast majority of more than 300 other kinases, including RIP1. RIP1 inhibitor Nec-1 (30 &,micro,M, Cat. Nos. 480065 &, 505224) can be employed in conjunction with GSK&prime,872 (3 µ,M) in delineating RIP1- vs. RIP3-dependency in Toll-like receptors- (TLRs) mediated necrosis and TNFR1-initiated necroptosis in the presence or absence of caspase inhibitor Z-VAD-FMK (25 &,micro,M, Cat. Nos. 627609 &, 627610).